Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C

Virulence

Volumn 3, Issue 7, 2012, Pages

  Losikoff, Phyllis T ^a   Self, Alyssa A ^a   Gregory, Stephen H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Chronic liver disease; Dendritic cells; Hepatitis C; Tolerance

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

CD4+ T LYMPHOCYTE; CELL INTERACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; VIRUS GENOME; VIRUS MORPHOLOGY; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; VIROLOGY;

DENDRITIC CELLS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; T-LYMPHOCYTES, REGULATORY;

EID: 84870908918     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.21823     Document Type: Review

References (139)

1. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67:1385-95; PMID:7679746
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-905; PMID:1280771; http://dx.doi.org/10. 1056/NEJM199212313272702
3. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36(Suppl 1): S74-83; PMID:12407579; http://dx.doi.org/10.1002/hep.1840360710
4. Healthcare-associated hepatitis B and C outbreaks reported to the Centers for Disease Control and Prevention (CDC) in 2008-2011. CDC Website 2012.
5. Brown RS, Jr., Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003; 9:S10-3; PMID: 14586889; http://dx.doi.org/10.1053/jlts.2003.50244
6. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493-9; PMID:9819447; http://dx. doi.org/10.1056/NEJM199811193392102
7. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142:1340-50, e1; PMID:22537441; http://dx.doi.org/10.1053/j.gastro. 2012.02.015
8. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-9; PMID:11029989; http://dx. doi.org/10.2105/AJPH.90.10.1562
9. Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004; 190:1270-4; PMID:15346337; http://dx.doi.org/10.1086/423943
10. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009; 10:1819-37; PMID:19891557; http://dx.doi.org/10.2217/pgs.09. 121
11. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 2012; 19:173-81; PMID:22329371; http://dx.doi.org/10.1111/j.1365-2893.2011.01497.x
12. Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240-4; PMID:9425943; http://dx.doi.org/10.1002/hep.510270136
13. Neumann-Haefelin C. [Protective role of HLA-B27 in HIV and hepatitis C virus infection]. Dtsch Med Wochenschr 2011; 136:320-4; PMID:21302207; http://dx.doi.org/10.1055/s-0031-1272531
14. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512; PMID:10790425; http://dx.doi.org/10.1084/jem.191.9.1499
15. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209:61-75; PMID:22213804; http://dx.doi.org/10.1084/jem.20100388
16. Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76:12584-95; PMID:12438584; http://dx.doi.org/10.1128/JVI.76.24.12584-12595.2002
17. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol 2007; 13: 2416-26; PMID:17552024
18. Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010; 51:378-87; PMID: 19918975; http://dx.doi.org/10.1002/hep.23319
19. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 2005; 201:1725-31; PMID: 15939788; http://dx.doi.org/10.1084/jem.20042284
20. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37:1189-98; PMID:12717401; http://dx.doi. org/10.1053/jhep.2003.50194
21. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550-8; PMID: 11356962; http://dx.doi.org/10.1128/JVI.75.12. 5550-5558.2001
22. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:3447-58; PMID:12218168
23. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40:1062-71; PMID: 15486925; http://dx.doi.org/10.1002/hep.20454
24. Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007; 47:316-24; PMID:17475362; http://dx.doi.org/10.1016/j.jhep.2007.03.023
25. Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol 2010; 52:315-21; PMID:20129690; http://dx.doi.org/10.1016/j.jhep.2009.12.013
26. Gowans EJ, Jones KL, Bharadwaj M, Jackson DC. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol 2004; 30: 283-90; PMID:15163415; http://dx.doi.org/10.1016/j.jcv.2004.03.006
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588
28. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82:487-93; PMID:7525461
29. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165:6037-46; PMID:11086035
30. Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci 2009; 14: 808-17; PMID:19273101; http://dx.doi.org/10.2741/3279
31. Tavakoli S, Mederacke I, Herzog-Hauff S, Glebe D, Grün S, Strand D, et al. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 2008; 151:61-70; PMID:18031557; http://dx.doi.org/10.1111/j.1365-2249.2007.03547.x
32. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151-61; PMID: 11913066; http://dx.doi.org/10.1038/nri746
33. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23:275-306; PMID:15771572; http://dx. doi.org/10.1146/annurev.immunol.23.021704.115633
34. Barchet W, Cella M, Colonna M. Plasmacytoid dendritic cells-virus experts of innate immunity. Semin Immunol 2005; 17:253-61; PMID:15990333; http://dx.doi.org/10.1016/j.smim.2005.05.008
35. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29:163-83; PMID:21219184; http://dx.doi.org/10.1146/annurev-immunol-031210-101345
36. Averill L, Lee WM, Karandikar NJ. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol 2007; 123:40-9; PMID:17239662; http://dx.doi.org/10.1016/j.clim. 2006.12.001
37. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194:863-9; PMID:11561001; http://dx.doi.org/10.1084/jem.194.6.863
38. de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Aït-Yahia S, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160:1666-76; PMID:9469423
39. Ulsenheimer A, Gerlach JT, Jung MC, Gruener N, Wächtler M, Backmund M, et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 2005; 41:643-51; PMID: 15726647; http://dx.doi.org/10.1002/hep.20592
40. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-26; PMID:15549123; http://dx.doi.org/10. 1038/ni1141
41. Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A 2010; 107:7431-6; PMID:20231459; http://dx.doi.org/10.1073/pnas.1002301107
42. Mengshol JA, Golden-Mason L, Castelblanco N, Im KA, Dillon SM, Wilson CC, et al. Virahep-C Study Group. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 2009; 58:964-73; PMID:19193669; http://dx. doi.org/10.1136/gut.2008.168948
43. Hellman P, Eriksson H. Early activation markers of human peripheral dendritic cells. Hum Immunol 2007; 68:324-33; PMID:17462499; http://dx.doi. org/10.1016/j.humimm.2007.01.018
44. Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 2005; 210:237-47; PMID: 16164031; http://dx.doi.org/10.1016/j.imbio.2005.05.018
45. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127:1513-24; PMID: 15521019; http://dx.doi.org/10.1053/j.gastro.2004.08.067
46. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J. Synergism of Toll-like receptorinduced interleukin-12p70 secretion by monocytederived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 2007; 247:72-84; PMID: 17927969; http://dx.doi.org/10.1016/j.cellimm.2007.07.008
47. Ryan EJ, O'Farrelly C. The affect of chronic hepatitis C infection on dendritic cell function: a summary of the experimental evidence. J Viral Hepat 2011; 18: 601-7; PMID:21794024; http://dx.doi.org/10.1111/j. 1365-2893.2011.01453.x
48. Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 2004; 40:335-45; PMID:15368438; http://dx.doi.org/10.1002/hep.20306
49. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-54; PMID: 19587449; http://dx.doi.org/10.1172/JCI39133
50. Cicinnati VR, Kang J, Sotiropoulos GC, Hilgard P, Frilling A, Broelsch CE, et al. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J Gen Virol 2008; 89:1243-53; PMID: 18420803; http://dx.doi.org/10.1099/vir.0.83517-0
51. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J Hepatol 2002; 36:734-41; PMID:12044522; http://dx.doi.org/10.1016/S0168-8278(02)00062-4
52. Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld L, Nischalke HD, et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 2006; 44:945-54; PMID:17006905; http://dx.doi.org/10.1002/hep. 21350
53. Wald O, Weiss ID, Galun E, Peled A. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine 2007; 39:50-62; PMID: 17629707; http://dx.doi.org/10.1016/j.cyto.2007.05. 013
54. Sozzani S, Allavena P, Vecchi A, Mantovani A. Chemokines and dendritic cell traffic. J Clin Immunol 2000; 20:151-60; PMID:10941822; http://dx.doi.org/10.1023/A:1006659211340
55. Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 1999; 189:611-4; PMID:9989975; http://dx.doi.org/10.1084/jem.189.4.611
56. Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004; 103:1026-9; PMID:14525790; http://dx. doi.org/10.1182/blood-2003-04-1339
57. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 2005; 192:497-503; PMID:15995965; http://dx.doi.org/10.1086/431523
58. Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005; 42:61-7; PMID:15629508; http://dx. doi.org/10.1016/j.jhep.2004.09.014
59. Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 2007; 204:2423-37; PMID:17893202; http://dx.doi. org/10.1084/jem.20070814
60. Barnes E, Salio M, Cerundolo V, Francesco L, Pardoll D, Klenerman P, et al. Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat 2008; 15:219-28; PMID:18194173; http://dx. doi.org/10.1111/j.1365-2893.2007.00934.x
61. Liang CC, Liu CH, Lin YL, Liu CJ, Chiang BL, Kao JH. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol 2011; 83:1212-20; PMID:21567425; http://dx. doi.org/10.1002/jmv.22096
62. Albert ML, Decalf J, Pol S. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. J Hepatol 2008; 49:1069-78; PMID:18929418; http://dx.doi. org/10.1016/j.jhep.2008.09.002
63. Canaday DH, Burant CJ, Jones L, Aung H, Woc-Colburn L, Anthony DD. Preserved MHC-II antigen processing and presentation function in chronic HCV infection. Cell Immunol 2011; 266:187-91; PMID: 21055734; http://dx.doi.org/10.1016/j.cellimm.2010.10.003
64. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162:5584-91; PMID:10228041
65. Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, Inchauspé G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120:512-24; PMID: 11159892; http://dx.doi.org/10.1053/gast.2001. 21212
66. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97:3171-6; PMID:11342445; http://dx.doi.org/10. 1182/blood.V97.10.3171
67. Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 2004; 172: 4907-16; PMID:15067070
68. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin Exp Immunol 2004; 137:559-65; PMID:15320906; http://dx.doi.org/10.1111/j.1365-2249.2004.02550.x
69. Della Bella S, Crosignani A, Riva A, Presicce P, Benetti A, Longhi R, et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology 2007; 121:283-92; PMID:17462079; http://dx.doi.org/10. 1111/j.1365-2567.2007.02577.x
70. Yonkers NL, Rodriguez B, Milkovich KA, Asaad R, Lederman MM, Heeger PS, et al. TLR liganddependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol 2007; 178:4436-44; PMID:17372001
71. Dolganiuc A, Szabo G. Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol 2011; 46:432-47; PMID:21327958; http://dx.doi.org/10.1007/s00535-011-0377-y
72. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L, Jr., et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro-and antiinflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 2003; 170:5615-24; PMID:12759441
73. Gelderblom HC, Nijhuis LE, de Jong EC, te Velde AA, Pajkrt D, Reesink HW, et al. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int 2007; 27:944-53; PMID:17696933; http://dx.doi.org/10.1111/j.1478-3231.2007.01507.x
74. MacDonald AJ, Semper AE, Libri NA, Rosenberg WM. Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells. Clin Exp Immunol 2007; 148:494-500; PMID:17362265; http://dx.doi.org/10. 1111/j.1365-2249.2007.03367.x
75. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 2004; 190:1919-26; PMID:15529255; http://dx.doi.org/10.1086/425425
76. Saito K, Ait-Goughoulte M, Truscott SM, Meyer K, Blazevic A, Abate G, et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 2008; 82:3320-8; PMID:18216090; http://dx.doi.org/10.1128/JVI.02547-07
77. Brady MT, MacDonald AJ, Rowan AG, Mills KH. Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol 2003; 33:3448-57; PMID: 14635055; http://dx.doi.org/10.1002/eji.200324251
78. Gerlach JT, Ulsenheimer A, Grüner NH, Jung MC, Schraut W, Schirren CA, et al. Minimal T-cellstimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol 2005; 79:12425-33; PMID:16160170; http://dx.doi.org/10. 1128/JVI.79.19.12425-12433.2005
79. Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology 2008; 135:2119-27; PMID: 18835391; http://dx.doi.org/10.1053/j.gastro.2008.07.082
80. Amjad M, Abdel-Haq N, Faisal M, Kamal M, Moudgal V. Decreased interferon-a production and impaired regulatory function of plasmacytoid dendritic cells induced by the hepatitis C virus NS 5 protein. Microbiol Immunol 2008; 52:499-507; PMID: 18822084; http://dx.doi.org/10.1111/j.1348-0421. 2008.00067.x
81. Pachiadakis I, Chokshi S, Cooksley H, Farmakiotis D, Sarrazin C, Zeuzem S, et al. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol 2009; 131:415-25; PMID:19303818; http://dx.doi. org/10.1016/j.clim.2009.02.001
82. Krishnadas DK, Ahn JS, Han J, Kumar R, Agrawal B. Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int Immunol 2010; 22:491-502; PMID: 20410260; http://dx.doi.org/10.1093/intimm/dxq033
83. Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-a and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 2006; 177:6758-68; PMID:17082589
84. Takaki A, Tatsukawa M, Iwasaki Y, Koike K, Noguchi Y, Shiraha H, et al. Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells. J Viral Hepat 2010; 17:555-62; PMID: 19804500; http://dx.doi.org/10.1111/j.1365-2893. 2009.01213.x
85. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol 2003; 77:10862-71; PMID:14512536; http://dx.doi.org/10. 1128/JVI.77.20.10862-10871.2003
86. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008; 128:133-47; PMID:18514579; http://dx.doi. org/10.1016/j.clim.2008.03.525
87. Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, et al. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol 1998; 28:3448-55; PMID:9842887; http://dx. doi.org/10.1002/(SICI)1521-4141(199811)28: 11,3448::AID-IMMU3448.3.0.CO;2-5
88. Landi A, Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Human dendritic cells expressing hepatitis C virus core protein display transcriptional and functional changes consistent with maturation. J Viral Hepat 2011; 18:700-13; PMID:20701679; http://dx. doi.org/10.1111/j.1365-2893.2010.01357.x
89. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998; 282:480-3; PMID:9774276; http://dx.doi.org/10.1126/science.282.5388.480
90. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500; PMID: 20559327; http://dx.doi.org/10.1038/nri2785
91. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20-1; PMID:11137993; http://dx.doi.org/10.1038/83713
92. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4:337-42; PMID: 12612581; http://dx.doi.org/10.1038/ni909
93. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*). Annu Rev Immunol 2009; 27:551-89; PMID:19302048; http://dx.doi.org/10.1146/annurev.immunol.021908.132723
94. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9:239-44; PMID:18285775; http://dx.doi.org/10.1038/ni1572
95. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635-46; PMID:17919943; http://dx.doi.org/10.1016/j. immuni.2007.08.014
96. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30:626-35; PMID:19464985; http://dx.doi.org/10.1016/j. immuni.2009.05.002
97. Miyara M, Sakaguchi S. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol 2011; 89:346-51; PMID: 21301480; http://dx.doi.org/10.1038/icb.2010.137
98. Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci 2012; 69:1997-2008; PMID:22205213; http://dx.doi.org/10.1007/s00018-011-0907-z
99. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002; 196:255-60; PMID:12119350; http://dx.doi. org/10.1084/jem.20020394
100. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006; 107:3925-32; PMID: 16418326; http://dx.doi.org/10.1182/blood-2005-11-4502
101. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006; 214:229-38; PMID:17100888; http://dx. doi.org/10.1111/j.1600-065X.2006.00445.x
102. La Cava A, Van Kaer L, Fu-Dong-Shi. CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol 2006; 27:322-7; PMID:16735139; http://dx.doi.org/10.1016/j.it.2006.05.003
103. Shevach EM. Mechanisms of foxp3+ T regulatory cellmediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx.doi.org/10.1016/j. immuni.2009.04.010
104. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3:253-7; PMID:12658273; http://dx.doi.org/10.1038/nri1032
105. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13:108-16; PMID:17257897; http://dx.doi.org/10. 1016/j.molmed.2007.01.003
106. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-betadependent manner. J Exp Med 2008; 205:1975-81; PMID:18710931; http://dx.doi.org/10.1084/jem. 20080308
107. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-9; PMID:1436033; http://dx.doi.org/10.1038/359693a0
108. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-32; PMID:18566595; http://dx.doi.org/10.1038/nri2343
109. Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 2011; 23:424-30; PMID:22055883; http://dx.doi.org/10.1016/j.smim.2011.10.002
110. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-32; PMID:17449799; http://dx.doi.org/10.1182/blood-2006-12-064527
111. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J 2009; 23:1685-93; PMID:19211924; http://dx.doi.org/10. 1096/fj.08-126458
112. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-65; PMID:17502665; http://dx.doi.org/10. 1084/jem.20062512
113. Ren X, Ye F, Jiang Z, Chu Y, Xiong S, Wang Y. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ 2007; 14:2076-84; PMID: 17762882; http://dx.doi.org/10.1038/sj.cdd.4402220
114. Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109:2058-65; PMID:17110462; http://dx.doi. org/10.1182/blood-2006-04-016451
115. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332:600-3; PMID: 21474713; http://dx.doi.org/10.1126/science.1202947
116. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21:503-13; PMID:15485628; http://dx.doi.org/10.1016/j.immuni.2004.08.010
117. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180:5916-26; PMID: 18424711
118. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008; 28:402-13; PMID: 18328743; http://dx.doi.org/10.1016/j.immuni.2008.01.012
119. Li S, Jones KL, Woollard DJ, Dromey J, Paukovics G, Plebanski M, et al. Defining target antigens for CD25+ FOXP3 + IFN-c-regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol 2007; 85:197-204; PMID:17199111
120. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 2002; 185:720-7; PMID:11920289; http://dx.doi.org/10.1086/339340
121. Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Jr., Tester IA, Wang CC, et al. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008; 197:46-57; PMID:18171284; http://dx.doi. org/10.1086/523651
122. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005; 79: 7860-7; PMID:15919940; http://dx.doi.org/10.1128/JVI.79.12.7860-7867.2005
123. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38:1437-48; PMID:14647055
124. Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008; 82:5043-53; PMID:18337568; http://dx.doi.org/10. 1128/JVI.01548-07
125. Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, et al. Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog 2009; 5:e1000707; PMID:20041222; http://dx.doi.org/10. 1371/journal.ppat.1000707
126. Langhans B, Braunschweiger I, Arndt S, Schulte W, Satoguina J, Layland LE, et al. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond) 2010; 119:97-109; PMID:20222873; http://dx.doi.org/10.1042/CS20090661
127. Cusick MF, Schiller JJ, Gill JC, Eckels DD. Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses. Clin Dev Immunol 2011; 2011:806061; PMID: 21197453; http://dx.doi.org/10.1155/2011/806061
128. Mishiro S, Takeda K, Hoshi Y, Yoshikawa A, Gotanda T, Itoh Y. An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen. Autoimmunity 1991; 10:269-73; PMID:1723001; http://dx.doi.org/10.3109/08916939109001900
129. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005; 79: 7852-9; PMID:15919939; http://dx.doi.org/10.1128/JVI.79.12.7852-7859.2005
130. Heeg MH, Ulsenheimer A, Grüner NH, Zachoval R, Jung MC, Gerlach JT, et al. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology 2009; 137:1280-8, e1-6; PMID:19596013; http://dx.doi.org/10.1053/j.gastro. 2009.06.059
131. Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis 2005; 192:258-65; PMID: 15962220; http://dx.doi.org/10.1086/430949
132. Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferongamma signaling in T cell lines. Virology 2007; 361: 161-73; PMID:17175001; http://dx.doi.org/10.1016/j.virol.2006.11.009
133. Ludwig IS, Lekkerkerker AN, Depla E, Bosman F, Musters RJ, Depraetere S, et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol 2004; 78:8322-32; PMID: 15254204; http://dx.doi.org/10.1128/JVI.78.15. 8322-8332.2004
134. Dominguez-Villar M, Fernandez-Ponce C, Munoz-Suano A, Gomez E, Rodríguez-Iglesias M, Garcia-Cozar F. Up-regulation of FOXP3 and induction of suppressive function in CD4+ Jurkat T-cells expressing hepatitis C virus core protein. Clin Sci (Lond) 2012; 123:15-27; PMID:22214248; http://dx.doi.org/10. 1042/CS20110631
135. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi. org/10.1146/annurev.immunol.21.120601.141040
136. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010; 108:111-65; PMID:21056730; http://dx.doi. org/10.1016/B978-0-12-380995-7.00004-5
137. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun 2010; 34:1-6; PMID:19717280; http://dx.doi.org/10.1016/j.jaut. 2009.08.008
138. Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP, et al. Human liver dendritic cells promote T cell hyporesponsiveness. J Immunol 2009; 182:1901-11; PMID:19201843; http://dx.doi. org/10.4049/jimmunol.0803404
139. Cobbold SP, Adams E, Nolan KF, Regateiro FS, Waldmann H. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol Rev 2010; 236:203-18; PMID:20636819; http://dx. doi.org/10.1111/j.1600-065X.2010.00913.x